Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

572.00INR
19 Jan 2018
Change (% chg)

Rs-4.25 (-0.74%)
Prev Close
Rs576.25
Open
Rs577.10
Day's High
Rs579.95
Day's Low
Rs568.50
Volume
331,179
Avg. Vol
466,319
52-wk High
Rs728.45
52-wk Low
Rs433.15

Select another date:

Tue, Jan 16 2018

BRIEF-Allergan, Ironwood Announce Settlement With Sun Pharma

* IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH SUN PHARMA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION

MEDIA-US FDA may inspect Sun Pharma's Halol site in Feb - Economic Times

- Note: Reuters has not verified this story and does not vouch for its accuracy

BUZZ-India's Sun Pharma hits 5-month high after U.S. FDA accepts new drug application

** Shares of Sun Pharmaceutical Industries Ltd climb as much as 6.4 pct to 576 rupees, highest since July 27

BRIEF-Sun Pharmaceutical Industries Announces U.S FDA Acceptance Of NDA For OTX-101

* ANNOUNCES U.S FDA ACCEPTANCE OF NDA FOR OTX-101 Source text - http://bit.ly/2BDUZEZ Further company coverage:

BRIEF-Sun Pharmaceutical Industries Reports 12.3 Percent Stake In Scpharmaceuticals As Of November 21

* SUN PHARMACEUTICAL INDUSTRIES LIMITED REPORTS 12.3 PERCENT STAKE IN SCPHARMACEUTICALS INC AS OF NOVEMBER 21 - SEC FILING‍​

BUZZ-India's Sun Pharma slides on recall of diabetes drug

** Shares of Sun Pharmaceutical Industries Ltd slip as much as 2.1 pct at 538.25 rupees, post their biggest intraday percentage loss since Nov 15

BUZZ-India's Sun Pharmaceutical Industries falls on weak Q2 earnings

** Sun Pharmaceutical Industries Ltd drops as much as 3.1 pct to 510 rupees, lowest since Oct 4

BRIEF-Sun Pharma Industries MD says no new updates on Halol; awaiting FDA re-inspection of plants‍​

Nov 14 Sun Pharmaceutical Industries managing director Dilip Shanghvi says:

Sun Pharma posts profit dive on U.S. pricing pressure

India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States.

UPDATE 1-India's Sun Pharma posts profit dive on U.S. pricing pressure

* Q2 profit down 59 pct * Indian sales rise 11 pct * U.S. sales down 44 pct (Adds detail, executive comment) Nov 14 India's largest drugmaker Sun Pharmaceutical Industries reported a 59 percent plunge in second-quarter profit on Tuesday, hurt by generics pricing pressure in the United States. Along with other Indian drugmakers, Sun Pharma has had sales dented by rising competition in the generics market and greater pricing scrutiny in the United States,

Select another date: